Skip to Main text

Southeast Asia

Press Release 2021

2021/Jun/15

Development of HSP47 siRNA drug ND-L02-s0201 for fibrosis

Achievement of Milestone related to License Agreement of ND-L02-s0201

Nitto Denko Corporation (Headquarters: Osaka, Japan; President, CEO & COO: Hideo Takasaki; “Nitto”, hereafter) (6988:Tokyo) today announced achievement of predefined milestone by Bristol Myers Squibb Company (“BMS”, hereafter) (NYSE: BMY), based on the exclusive license agreement of ND-L02-s0201 (BMS-986263) for advanced liver fibrosis signed with BMS in 2016. The company will receive milestone payment from BMS. Per the agreement, Nitto does not disclose detail of milestone payment.

ND-L02-s0201 is siRNA oligonucleotide drug designed to inhibit HSP47 (Heat Shock Protein 47), a collagen specific chaperone which regulates collagen synthesis and secretion and causes fibrosis. In November 2016, BMS and Nitto have entered into an agreement granting BMS exclusive worldwide rights for the development and commercialization of ND-L02-s0201 for the treatment of advanced liver fibrosis.

Nitto, as a manufacturer striving to shape the future through technology, will continue to contribute to the realization of a better society and the environment through development of new products and applications.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Contact Us

For any inquiries about this press release.

Nitto Denko Singapore Pte. Ltd.
Notice
Here is the information at the release day. This information may be different from the information at other medias. Please be forewarned.

Related Information

Back to Page Top